Outpatient Surgery Magazine

Manager's Guide to Surgery's Ambulatory Anesthesia - July 2015

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://magazine.outpatientsurgery.net/i/538156

Contents of this Issue

Navigation

Page 3 of 68

4 S U P P L E M E N T T O O U T P A T I E N T S U R G E R Y M A G A Z I N E J U LY 2 0 1 5 Keep cool in the crisis with administration in When MH strikes, LESS THAN 1 MINUTE Please see Brief Summary of full Prescribing Information on the following page. References: 1. Data on le. Eagle Pharmaceuticals, Inc. 2. Managing an MH crisis. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/healthcareprofessionals/managing-a-crisis. Accessed June 18, 2014. 3. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014. 4. Dantrium Intravenous [package insert]. Rochester, MI: JHP Pharmaceuticals, LLC; 2008. 5. Revonto [package insert]. Louisville, KY: US WorldMeds, LLC; 2011. INDICATION RYANODEX ® (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk. IMPORTANT SAFETY INFORMATION RYANODEX ® is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia (MH), including: • Discontinuing triggering anesthetic agents • Increasing oxygen • Managing the metabolic acidosis • Instituting cooling when necessary • Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX ® is insuf cient to maintain diuresis) © 2014 Eagle Pharmaceuticals, Inc. All rights reserved. 50 Tice Blvd, Suite 315 Woodcliff Lake, NJ 07677 (201) 326-5300 RYN14-0027-01 8/2014 ADVANCING THE STANDARD IN MALIGNANT HYPERTHERMIA (MH) TREATMENT. RYANODEX ® (dantrolene sodium) for injectable suspension is changing how MH is treated. • Less time for reconstitution and administration – Less than 1 minute for a loading dose (2.5 mg/kg) of dantrolene sodium in an MH crisis 1,2 • Less risk of complications with less uid – Over 99% less sterile water for injection than other dantrolene sodium IV treatments 3-5 • Less effort to stay cool in an MH crisis – 1 vial provides a loading dose for patients up to 100 kg and can be administered by 1 healthcare professional (eg, an anesthesia provider) 1,3 To request that RYANODEX ® be stocked in your institution or obtain ordering information, visit RYANODEX.com/ops or call 855.318.2170.

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Manager's Guide to Surgery's Ambulatory Anesthesia - July 2015